Industry reports
Editor highlights

Search inside this page

All regions

Free Market Research Guides to Download

Pharmaceutical Analysis & Statistics in Canada, April 2014

You might be interested in: therapeutics, cancer, drug, more »

» Purchase Premium Reports

1-50 of about 900 reports
PharmaPoint: Crohn's Disease - Canada Drug Forecast and Market Analysis to 2022

PharmaPoint: Crohn's Disease - Canada Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • January 2014
  • by Global Data

PharmaPoint: Crohn's Disease - Canada Drug Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds ...

  • Industries : Drug and Medication
  • Countries : Canada
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Canada Drug Forecast and Market Analysis to 2022

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Canada Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • January 2014
  • by Global Data

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Canada Drug Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute o ...

  • Industries : Drug and Medication
  • Countries : Canada
Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact Remains Distant

Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact Remains Distant

  • $ 3 500
  • Industry report
  • April 2014
  • by GBI Research

Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact Remains Distant Summary GBI Research, the leading ...

  • Industries : Therapy
  • Countries : World, Japan, Canada, Europe, United States, Spain, Italy, France, Germany, United Kingdom, North America
Prochymal (Crohn's Disease) - Forecast and Market Analysis to 2022

Prochymal (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Prochymal (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will ...

  • Industries : Pathology
  • Countries : Canada, World, United States, India, China
Stelara (Crohn's Disease) - Forecast and Market Analysis to 2022

Stelara (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Stelara (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge ...

  • Industries : Pathology
  • Countries : Canada, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, India, China, Europe
Tysabri (Crohn's Disease) - Forecast and Market Analysis to 2022

Tysabri (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Tysabri (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge ...

  • Industries : Pathology
  • Countries : China, World, Spain, Italy, France, Germany, United States, Canada, India, Europe
Vercirnon (Crohn's Disease) - Forecast and Market Analysis to 2022

Vercirnon (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Vercirnon (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will ...

  • Industries : Pathology
  • Countries : Canada, World, Spain, Italy, France, Germany, United States, United Kingdom, India, China, Europe
Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation ...

  • Industries : Drug and Medication
  • Countries : Canada, Germany, Spain, Italy, France, World, Europe, United States, United Kingdom, Japan
Ambirix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Ambirix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Ambirix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation ...

  • Industries : Drug and Medication
  • Countries : World, United Kingdom, Canada, Spain, Italy, France, Germany, Japan
Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation ...

  • Industries : Drug and Medication
  • Countries : Canada, Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation ...

  • Industries : Drug and Medication
  • Countries : Canada, Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Hexyon (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Hexyon (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Hexyon (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation ...

  • Industries : Drug and Medication
  • Countries : Canada, Spain, Italy, France, Germany, World, United States, United Kingdom, Europe, Japan
Infanrix Hexa (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Infanrix Hexa (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Infanrix Hexa (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic ...

  • Industries : Drug and Medication
  • Countries : Canada, Spain, Italy, France, Germany, World, United States, Europe, Japan
Pediarix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Pediarix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Pediarix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation ...

  • Industries : Drug and Medication
  • Countries : World, United States, Canada, Spain, Italy, France, Germany, Japan
Recombivax HB (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Recombivax HB (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Recombivax HB (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic ...

  • Industries : Drug and Medication
  • Countries : Canada, Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Twinrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Twinrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Twinrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation ...

  • Industries : Drug and Medication
  • Countries : Canada, Spain, Italy, France, Germany, World, United States, United Kingdom, Europe, Japan
North America Contrast Media Injectors Market Outlook to 2020

North America Contrast Media Injectors Market Outlook to 2020

  • $ 3 000
  • Industry report
  • March 2014
  • by Global Data

North America Contrast Media Injectors Market Outlook to 2020 Summary GlobalData's new report, "North America Contrast Media Injectors Market Outlook to 2020", provides key market data on the North America ...

  • Industries : Drug Delivery Technology
  • Countries : North America, United States, Mexico, Canada, World
Canada Contrast Media Injectors Market Outlook to 2020

Canada Contrast Media Injectors Market Outlook to 2020

  • $ 2 500
  • Industry report
  • March 2014
  • by Global Data

Canada Contrast Media Injectors Market Outlook to 2020 Summary GlobalData's new report, "Canada Contrast Media Injectors Market Outlook to 2020", provides key market data on the Canada Contrast Media Injectors ...

  • Industries : Drug Delivery Technology
  • Countries : Canada
Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2014

Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2014

  • $ 2 000
  • Industry report
  • March 2014
  • by Global Markets Direct

Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2014', provides an overview of ...

  • Industries : Drug and Medication
  • Countries : Canada, World
Canada Pharmaceuticals and Healthcare Industry Update Quarter 2 2012

Canada Pharmaceuticals and Healthcare Industry Update Quarter 2 2012

  • $ 1 300
  • Industry report
  • March 2014
  • by Business Monitor International

BMI View: With Canada’s economy set to weather the external storm, the outlook for the country’s pharmaceutical industry looks relatively stable. Over the longer-term an ageing population in this ...

  • Industries : Drug and Medication
  • Countries : Canada
Vitamins and Dietary Supplements Market Analysis in Canada

Vitamins and Dietary Supplements Market Analysis in Canada

  • $ 898
  • Industry report
  • March 2014
  • by Euromonitor International

Between 2006 and 2011, the number of Canadians over the age of 65 increased from 13% of the population to over 14% of the total population. Additionally, consumer surveys released in Canada indicate that ...

  • Industries : Vitamin and Supplement
  • Countries : Canada
Dermatologicals in Canada

Dermatologicals in Canada

  • $ 898
  • Industry report
  • March 2014
  • by Euromonitor International

Antifungals, , germicidals/antiseptics, and haemorrhoid treatments were the categories that gave dermatologicals a push towards higher than average growth in consumer health. Antifungals consists of topical ...

  • Industries : Drug and Medication
  • Countries : Canada
NRT Smoking Cessation Aids Market Analysis in Canada

NRT Smoking Cessation Aids Market Analysis in Canada

  • $ 898
  • Industry report
  • March 2014
  • by Euromonitor International

This increase was due in large part to the combined efforts of anti-smoking organisations and government initiatives to curb smoking in Canada. Provinces across Canada have bans on smoking in public areas ...

  • Industries : Drug and Medication
  • Countries : Canada
Analgesics Market Overview in Canada

Analgesics Market Overview in Canada

  • $ 898
  • Industry report
  • March 2014
  • by Euromonitor International

Sales of analgesics continued to show strong growth of 4% in 2010, reaching C$766 million in current value terms. Growth was largely driven by Canada’s rapidly ageing population as seniors increasingly ...

  • Industries : Drug and Medication
  • Countries : Canada
Digestive Remedies Market Overview in Canada

Digestive Remedies Market Overview in Canada

  • $ 898
  • Industry report
  • March 2014
  • by Euromonitor International

Retail sales of digestive remedies registered a solid growth of 3%, reaching current value sales of C$363 million in 2010. The rapidly ageing population in Canada as well as rising incidence of indigestion ...

  • Industries : Over-the-counter Drug
  • Countries : Canada
Sandoz International GmbH SWOT Analysis, Strategy, Revenues and Profits

Sandoz International GmbH SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • April 2014
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

  • Industries : Generic Drug
  • Countries : Germany, India, Argentina, Brazil, Canada, Slovenia, Poland, Austria
Microbix Biosystems Inc. (Symbol:MBX) SWOT Analysis, Strategy, Revenues and Profits

Microbix Biosystems Inc. (Symbol:MBX) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • April 2014
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

  • Industries : Pathology
  • Countries : Canada
ALDA Pharmaceuticals Corp. (Symbol:APH) SWOT Analysis, Strategy, Revenues and Profits

ALDA Pharmaceuticals Corp. (Symbol:APH) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • April 2014
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

  • Industries : Pharmaceutical
  • Countries : Canada
Medtrode Inc. SWOT Analysis, Strategy, Revenues and Profits

Medtrode Inc. SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • February 2014
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

  • Industries : Drug Discovery and Development
  • Countries : United States, Canada
iCo Therapeutics Inc. (Symbol:ICO) SWOT Analysis, Strategy, Revenues and Profits

iCo Therapeutics Inc. (Symbol:ICO) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • February 2014
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

  • Industries : Therapy
  • Countries : Canada

» View Public Reports

About 1 500 reports

Canada: Demographic Snapshot, March 2014

  • Country report
  • March 2014
  • 9 pages
  • by Research Paper

... Of preterm birth showed distinct differ- ences (table 5). Gestational diabetes and other chronic medical disease were weakly or moderately associated with spontaneous preterm birth, while hypertension ...


» Read our Company Profiles

19 Companies

GlaxoSmithKline P.L.C.

United States

GlaxoSmithKline PLC

United Kingdom

Johnson and Johnson

United States

AstraZeneca PLC

United Kingdom

Pfizer Inc.

United States

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.